小澤 洋子 (オザワ ヨウコ)

Ozawa, Yoko



医学部 眼科学教室 (信濃町)




プロフィール 【 表示 / 非表示

  • Yoko Ozawa M.D., Ph.D. works as a Chief of the Medical Retina Division (Age-related macular disease; AMD division) and a Vitreoretinal Surgeon, as well as a Lab Chief of the Laboratory of Retinal Cell Biology (RCB lab). Her recent research interest is the aging and neuroprotection of the retina, and its association with oxidative stress and inflammation. One of her missions is to find a neuroprotective treatment for the retinal diseases, such as AMD, diabetic retinopathy, and retinitis pigmentosa. During her training of the vitreoretinal surgery, she has become aware that simple surgical therapies do not always rescue the patients’ retina, and the additional approaches may be required for further improvement of the retinal conditions. Therefore, she joined a basic research lab, the Department of Physiology, Keio University School of Medicine, Prof. Hideyuki Okano’s Lab, for mastering neurobiology of the retina, including development and regeneration. After taking the Ph.D., she returned to Department of Ophthalmology, and started her research for learning the pathophysiology of the retinal diseases and exploring new therapeutic approaches.

学歴 【 表示 / 非表示

  • 1986年04月

    慶應義塾大学, 医学部

    日本, 大学, 卒業

学位 【 表示 / 非表示

  • 医学博士, 慶應義塾大学, 論文, 2008年

免許・資格 【 表示 / 非表示

  • 医師免許


研究分野 【 表示 / 非表示

  • 眼科学

研究キーワード 【 表示 / 非表示

  • 神経保護、老化、酸化ストレス、炎症

研究テーマ 【 表示 / 非表示

  • 網膜病態の分子メカニズム, 


共同研究希望テーマ 【 表示 / 非表示

  • 感覚器老化


著書 【 表示 / 非表示

  • Oxidative Stress in the RPE and Its Contribution to AMD Pathogenesis: Implication of Light Exposure.

    Ozawa, Y., Springer Japan., 2014年

  • Lutein and Oxidative Stress-Mediated Retinal Neurodegeneration in Diabetes

    Ozawa, Y. and Sasaki, M., PREEDY Diabetes., 2013年

  • Angiogenesis in Response to Hypoxia

    Ozawa, Y., Tsubota, K. and Okano, H., 2010年

論文 【 表示 / 非表示

  • Optic neuropathy causing vertical unilateral hemianopsia after pars plana vitrectomy for a macular hole: A case report

    Kawashima, H., Nagai, N., Shinoda, H., Tsubota, K. and Ozawa, Y.

    Medicine (Baltimore) 97 ( 17 ) e0321 2018年04月

    査読有り,  ISSN  0025-7974


    INTRODUCTION: Recent progress in medical technology has resulted in improved surgical outcomes of pars plana vitrectomy (PPV); with microincision systems, the incidence of procedure-related complications during surgery has been reduced. However, unpredictable visual field defects after PPV remain an unresolved issue. A few reports have shown that damage to the retinal neurofibers owing to dry-up during air/fluid exchange or retinal neurotoxicity of the dye used to visualize the internal limiting membrane (ILM), as well as unintentional removal of retinal neurofibers during ILM peeling, are responsible for such visual field disorders. In this report, we present a case of extensive visual field defect due to optic neuropathy exhibiting vertical hemianopsia after PPV. CASE SUMMARY: A 50-year-old woman underwent PPV and cataract surgery for a macular hole and mild cataract under retrobulbar anesthesia with 3.5 mL of xylocaine. At the time of opening an infusion cannula for PPV, the intraocular lens was herniating, with an acute increase in pressure from the posterior eyeball; thus, intraocular pressure configuration level had to be decreased from the default level, whereas the other procedures including 20% SF6 injection were performed without any modification. The macular hole was closed postoperatively. However, the patient experienced nasal hemianopsia, which turned out to be optic neuropathy, as assessed via electric physiological examinations. The pattern of the visual field defect was not typical for glaucoma or anterior ischemic optic neuropathy. Her optic nerve head was pale at the temporal side soon after the surgery, and her blood pressure was low, suggesting that there may have been a congestion of the optic nerve feeder vessels because of the relatively high pressure in the orbit. The space occupancy with xylocaine and extensively stretched and plumped out eye ball with infusion during PPV may have pressed the surrounding tissue of the optic nerve and the feeder vessels. CONCLUSION: PPV is safe for most patients; however, individual variations in local and/or systemic conditions may cause complications. Future studies to optimize the surgical condition for each individual patient may be warranted.

  • Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline

    Minami, S., Nagai, N., Suzuki, M., Kurihara, T., Sonobe, H., Kamoshita, M., Uchida, A., Shinoda, H., Takagi, H., Sonoda, S., Sakamoto, T., Tsubota, K. and Ozawa, Y.

    Sci Rep 8 ( 1 ) 58 2018年01月

    査読有り,  ISSN  2045-2322


    Currently, age-related macular degeneration (AMD) is treated while patients exhibit good best-corrected visual acuity (BCVA). However, previous clinical trials only include patients with poor BCVA. We prospectively analyzed the benefits of intravitreal aflibercept (IVA) treatment for AMD patients exhibiting good BCVA at baseline. Twenty-nine treatment-naive AMD patients (29 eyes) with BCVA better than 0.6 (74 letters in ETDRS chart) were treated with IVA once a month for 3 months and every 2 months thereafter with no additional treatments. Improvement in mean BCVA, measured using the conventional Landolt C chart, contrast VA chart, and functional VA (FVA) system, and reductions in mean central retinal thickness (CRT), central choroidal thickness, macular volume (MV), and choroidal area on optical coherence tomography images were observed at 6 and 12 months. Improvements in contrast VA and FVA scores, in contrast to conventional BCVA, correlated with MV reduction; no VA scores correlated with a reduced CRT. The MV correlated with choroidal area after IVA. No severe adverse events occurred. IVA improved visual function, retinal condition, and quality of life evaluated by Visual Function Questionnaire, and was beneficial in these patients. The contrast VA and FVA scores and MVs, which detect subtle changes, helped demonstrate the benefits.

  • Absolute and estimated values of macular pigment optical density in young and aged Asian participants with or without age-related macular degeneration

    Ozawa, Y., Shigeno, Y., Nagai, N., Suzuki, M., Kurihara, T., Minami, S., Hirano, E., Shinoda, H., Kobayashi, S. and Tsubota, K.

    BMC Ophthalmol 17 ( 1 ) 161 2017年08月

    査読有り,  ISSN  1471-2415


    BACKGROUND: Lutein and zeaxanthin are suggested micronutrient supplements to prevent the progression of age-related macular degeneration (AMD), a leading cause of blindness worldwide. To monitor the levels of lutein/zeaxanthin in the macula, macular pigment optical density (MPOD) is measured. A commercially available device (MPSII(R), Elektron Technology, Switzerland), using technology based on heterochromatic flicker photometry, can measure both absolute and estimated values of MPOD. However, whether the estimated value is applicable to Asian individuals and/or AMD patients remains to be determined. METHODS: The absolute and estimated values of MPOD were measured using the MPSII(R) device in 77 participants with a best-corrected visual acuity (BCVA) > 0.099 (logMAR score). RESULTS: The studied eyes included 17 young (20-29 years) healthy, 26 aged (>50 years) healthy, 18 aged and AMD-fellow, and 16 aged AMD eyes. The mean BCVA among the groups were not significantly different. Both absolute and estimated values were measurable in all eyes of young healthy group. However, absolute values were measurable in only 57.7%, 66.7%, and 43.8%, of the aged healthy, AMD-fellow, and AMD groups, respectively, and 56.7% of the eyes included in the 3 aged groups. In contrast, the estimated value was measurable in 84.6%, 88.9% and 93.8% of the groups, respectively, and 88.3% of eyes in the pooled aged group. The estimated value was correlated with absolute value in individuals from all groups by Spearman's correlation coefficient analyses (young healthy: R(2) = 0.885, P = 0.0001; aged healthy: R(2) = 0.765, P = 0.001; AMD-fellow: R(2) = 0.851, P = 0.0001; and AMD: R(2) = 0.860, P = 0.013). Using the estimated value, significantly lower MPOD values were found in aged AMD-related eyes, which included both AMD-fellow and AMD eyes, compared with aged healthy eyes by Student's t-test (P = 0.02). CONCLUSIONS: Absolute, in contrast to estimated, value was measurable in a limited number of aged participants; however, it was correlated with estimated value both in young and aged Asian populations with or without AMD. These results may inform future clinical studies investigating the measurement of MPOD in understanding the role of macular pigments in the pathogenesis of AMD.

  • Maculopapular rash after intravitreal injection of an antivascular endothelial growth factor, aflibercept, for treating age-related macular degeneration: A case report

    Nagai, N., Ibuki, M., Shinoda, H., Kameyama, K., Tsubota, K. and Ozawa, Y.

    Medicine (Baltimore) 96 ( 21 ) e6965 2017年05月

    査読有り,  ISSN  0025-7974


    RATIONALE: Aflibercept, an anti-vascular endothelial growth factor (VEGF) drug, is used for treatment of colon cancer as well as retinal diseases, including wet age-related macular degeneration (AMD). It is injected into the vitreous cavity of eyes for treatment of AMD. Although vascular suppression-including cardiovascular events-and local infection related to the injection procedure are well-known potential adverse events, pathological immune responses after intravitreal aflibercept (IVA) injection have not been described. PATIENT CONCERNS: A 60-year-old Japanese man diagnosed with polypoidal choroidal vasculopathy (PCV), a subtype of wet AMD, was treated by anti-VEGF injection. Ten hours after the last IVA injection, he presented with systemic erythema with itching. DIAGNOSES: On the basis of the palpable erythema and papules observed on the trunk and extremities, along with redness of the pharynx, the patient was diagnosed with maculopapular-type drug eruption. The findings of biopsy of erythematous skin on the back revealed lymphocyte infiltration and telangiectasia in the upper dermis, thus confirming the diagnosis. INTERVENTIONS: The patient was administered 30 mg prednisolone to resolve the immunoreaction. OUTCOMES: With this treatment, the eruption turned brown, and the pharyngeal lesion and itching were resolved, and the maculopapular rash after intravitreal IVA was resolved. LESSONS: This case illustrates the importance of medical staff being aware of aflibercept-a widely used anti-VEGF drug in various fields, including retinal diseases-as a potential cause of drug allergy.

  • Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice

    Sato, S., Shinoda, H., Nagai, N., Suzuki, M., Uchida, A., Kurihara, T., Kamoshita, M., Tomita, Y., Iyama, C., Minami, S., Yuki, K., Tsubota, K. and Ozawa, Y.

    Medicine (Baltimore) 96 ( 16 ) e6459 2017年04月

    査読有り,  ISSN  0025-7974


    Intravitreal ranibizumab (IVR) has been approved for treating diabetic macular edema (DME), and is used in daily clinical practice. However, the treatment efficacies of IVR monotherapy in real-world clinical settings are not well known.The medical records of 56 eyes from 38 patients who received their first IVR for DME between April 2014 and March 2015, and were retreated with IVR monotherapy as needed with no rescue treatment, such as laser photocoagulation, were retrospectively reviewed. The clinical course, best-corrected visual acuity (BCVA), and fundus findings at baseline, before the initial IVR injection, and at 12 months, were evaluated.Twenty-five eyes from 25 patients (16 men; mean age 68.7 +/- 9.8 years) who received IVR in the first eye, or unilaterally, without any other treatments during follow-up were included. After 12 months, mean central retinal thickness (CRT), which includes edema, was reduced (P = .003), although mean BCVA remained unchanged. There was a negative correlation between individual changes in BCVA (r = -0.57; P = .003) and CRT (r = -0.60; P = .002) at 12 months compared with baseline values. BCVA changes were greater in individuals with a history of pan-retinal photocoagulation at baseline (P = .026). After adjusting for age and sex, CRT improvement >100 mum at 12 months was associated with a greater CRT at baseline (OR 0.87 per 10 mum [95% CI 0.72-0.97]; P = .018) according to logistic regression analyses; however, better BCVA and CRT at 12 months were associated with a better BCVA (r = 0.77; P < .001) and lower CRT (r = 0.41; P = .039) at baseline, respectively, according to linear regression analyses.IVR monotherapy suppressed DME, and the effects varied according to baseline conditions. Eyes that had poorer BCVA or greater CRT, or a history of pan-retinal photocoagulation at baseline, demonstrated greater improvement with IVR monotherapy. In contrast, to achieve better outcome values, DME eyes should be treated before the BCVA and CRT deteriorate. These findings advance our understanding of the optimal use of IVR for DME in daily clinical practice, although further study is warranted.

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

全件表示 >>

研究発表 【 表示 / 非表示

  • Role of Angptl2 in laser-induced CNV.

    小澤 洋子

    International Retina Summit (China) , 2017年10月, 口頭(招待・特別)

  • Neuro-inflammation in Metabolic Syndrome.

    小澤 洋子

    14th International Ocular Inflammation Society Meeting in conjunction with SOIE. 4th Assembly. (Switzerland) , 2017年10月, 口頭(招待・特別)

  • Case Presentations and Panel Discussion.

    小澤 洋子

    11th Asia-Pacific Vitreo-retina Society (APVRS) Congress (Malaysia) , 2017年03月, シンポジウム・ワークショップ パネル(公募)

  • Inflammatory responses in AMD Pathogenesis.

    小澤 洋子

    32nd Asia-Pacific Academy of Ophthalmology (Singapore) , 2017年03月, 口頭(招待・特別)

  • Lutein/Zeaxanthin as a preventive approach for age-related macular degeneration.

    小澤 洋子

    The 3rd International Conference on Pharma and Food. (Japan) , 2016年11月, 口頭(招待・特別)

全件表示 >>

競争的資金等の研究課題 【 表示 / 非表示

  • iPS研究に基く神経変性疾患である網膜色素変性に対する新規神経保護治療法の開発


    文部科学省・日本学術振興会, 科学研究費助成事業, 小澤 洋子, 基盤研究(C), 補助金,  代表

  • 疾患iPS研究に基づく網膜色素変性症に対する新規神経保護治療薬の開発に向けた研究


    文部科学省・日本学術振興会, 科学研究費助成事業, 小澤 洋子, 基盤研究(C), 補助金,  代表

受賞 【 表示 / 非表示

  • Global Ophthalmology Awards Program Research Award


  • 慶應義塾大学医学部三四会奨励賞



担当授業科目 【 表示 / 非表示

  • 眼科学講義


担当経験のある授業科目 【 表示 / 非表示

  • 眼科

    慶應義塾, 2015年度, 専門科目, 講義